Cyclacel Pharma (CYCC) Tops Q3 EPS by 18c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. MSFT
6. NVDA
7. SPY
8. IBM
9. CRWV
10. SKYD

Go back to Cyclacel Pharma (CYCC) Tops Q3 EPS by 18c

Cyclacel Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

November 10, 2021 4:05 PM EST

- Second Phase 1/2 Study of Fadraciclib Now Enrolling Patients in Leukemia -- Cash Runway to Early 2023 -- Conference Call Scheduled November 10, 2021 at 4:30 p.m. ET -

BERKELEY HEIGHTS, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2021. The quarters business highlights include an update on the Companys progress with fadraciclib and CYC140, Cyclacel's novel CDK2/9 and PLK1... More